The Montreal Heart Institute announced COLCORONA clinical trial has provided clinically persuasive results of colchicine’s efficacy to treat COVID-19.

The study results show that colchicine reduces the risk of death or hospitalizations in patients with COVID-19 by 21% compared to placebo.

The analysis of the 4,159 patients in whom the diagnosis of COVID-19 was proven by a naso-pharyngeal PCR test has shown that the use of colchicine was associated with statistically significant reductions in the risk of death or hospitalization compared to placebo.

In these patients with a proven diagnosis of COVID-19, colchicine reduced hospitalizations by 25%, the need for mechanical ventilation by 50%, and deaths by 44%.

This major scientific discovery makes colchicine the world’s first oral drug that could be used to treat non-hospitalized patients with COVID-19.

Read More